MORE STORIES Britain's vaccine tsar warns first

New Post Public Reply Private Reply Replies (0) Message Board
Crunch55
363


MORE STORIES
Britain's vaccine tsar warns first approved Covid-19 jabs may be 'imperfect' and admits they may not work at all
By Vanessa Chalmers Health Reporter For Mailonline and Stephen Matthews Health Editor For Mailonline
13:33 28 Oct 2020, updated 14:56 28 Oct 2020

67
shares
227 comments
Kate Bingham, head of the UK's Vaccine Taskforce, dampened vaccine hopes
The first round of jabs, prioritised for the most at-risk, will be 'imperfect'
They may only reduce symptoms, rather than preventing infection
She has already said there were 'slim chances' of a jab before Christmas

Kate Bingham told the Financial Times less than half of the UK population will get a coronavirus vaccine if one is produced
Hopes of ending the Covid-19 pandemic with a vaccine were dealt a blow today as a senior British health chief warned the first approved jabs may not work.

ADVERTISEMENT

Kate Bingham, head of the UK's Vaccine Taskforce, has already warned there is only a 'slim' chance scientists will have a jab before Christmas.

And now she has dampened hopes even further, warning that the first generation of vaccines — which are all still in human trials — are 'likely to be imperfect'.


In a commentary published in medical journal The Lancet, Ms Bingham said: 'We should be prepared they might not prevent infection but rather reduce symptoms, and, even then, might not work for everyone or for long.'

And she added 'we do not know that we will ever have a vaccine at all', cautioning that 'many, and possibly all' of the vaccines currently being investigated could fail.

Ms Bingham was appointed chair of the UK's Vaccine Taskforce for Covid-19 in May and reports directly to the Prime Minister on the progress of a coronavirus vaccine, which experts say is key to controlling the pandemic.


Ms Bingham was appointed chair of the UK's Vaccine Taskforce for Covid-19 in May this year and reports directly to the Prime Minister on progress of a Covid-19 vaccine. She is pictured with a plaster on her arm after receiving the Novavax vaccine on Tuesday October 13

Ms Bingham said: 'The first generation of vaccines is likely to be imperfect, and we should be prepared that they might not prevent infection but rather reduce symptoms, and, even then, might not work for everyone or for long'
The taskforce, which Ms Bingham says was the 'brainchild of Sir Patrick Vallance' — Number 10's chief scientific adviser, is at the forefront of putting plans in place to get the UK population vaccinated.

'However, we do not know that we will ever have a vaccine at all. It is important to guard against complacency and over-optimism,' Ms Bingham said.


'The first generation of vaccines is likely to be imperfect, and we should be prepared that they might not prevent infection but rather reduce symptoms, and, even then, might not work for everyone or for long.'

COVID-19 VACCINE 'MAY NOT PREVENT SEVERE ILLNESS OR DEATH'
Covid-19 vaccines may not prevent people from getting severely sick or dying, Professor Peter Doshi, the associate editor of the British Medical Journal, has warned.

Trials of hundreds of thousands of volunteers are investigating whether experimental Covid-19 jabs stop a person from picking up the infection.

But Professor Doshi commented in a piece published last week that scientists are not waiting to see whether volunteers are protected from severe disease or death if they do catch it — which would only be the case if the vaccine didn't work very well — before they are rolled out.

This is a particular concern for the elderly, who are the most at risk of severe Covid-19 outcomes, because the vaccine may not be as effective at protecting them from catching the coronavirus in the first place.

Vaccines typically do not work as well for those over the age of 60 because they have an aged immune system.

Professor Doshi, of the University of Maryland, also revealed that the studies will not prove transmission between people can be curbed. Scientists are not measuring if those who catch it pass it on to friends and family, regardless of whether they get sick themselves.

None of the front-runners — Moderna, Pfizer, AstraZeneca, Janssen, Sinopharm, or Sinovac — are measuring if their vaccines will save lives in their final stage trials.

Scientists wait for a number of people to catch the coronavirus so they can compare whether the infection rates are higher in those who received the experimental Covid-19 jab, or in the placebo group.

If cases are higher in the placebo group, it would suggest that the vaccine protects against catching the coronavirus, in theory.

None of the phase three trials are waiting for endpoints of severe disease or deaths before stopping the trial, which would confirm the vaccine is indeed 'life-saving'.

But in response to Professor Doshi's paper, scientists say there are 'excellent' reasons for running the trials, the main one being to speed up finding a vaccine which could otherwise take years because so few Covid-19 patients become severely ill.

Dr Andrew Preston, a reader in microbial pathogenesis who works in vaccines, University of Bath, told MailOnline: 'Covering every manifestation of Covid disease would require trials so large, that run for such long times, that they are very likely to be impossible to run and fund, and would delay the data so long that we’d be living without any vaccine-mediated intervention for years to come.'

Commenting on the BMJ editorial, Dr Preston argued there were 'excellent and sensible reasons for running the trials as they are'.

'To test vaccines in the very vulnerable would require vaccinating vulnerable people and then asking them to put themselves in situations in which they might be exposed to the virus.

'The ethics of this would be highly questionable, so it makes sense to test whether the vaccine shows any effect in people who, if they did become infected, the consequences are far less severe.'

However, he agreed that it is important for there to be clarity on what vaccine trials will and will not show.

Experts say it is highly unlikely that any vaccine approved for the coronavirus will ever completely proven to work before it is rolled out.

ADVERTISEMENT
The World Health Organization admits 'no vaccine is 100 per cent effective'. For example, the measles jab, which has been doled out for decades, works 98 per cent of the time.

But if a jab prevents the large majority of people from catching the coronavirus, and potentially reduces the severity of the illness, then it will be hailed as game-changing.

RELATED ARTICLES
Dido Harding's Conservative MP husband blames 'chaotic parents' for sending children to school hungry - as Tory council leader claims those struggling to feed their children should shop at M&S
Ministers confirm ALL of Nottinghamshire will enter Tier 3 from Friday with shops banned from selling alcohol after 9pm, beauty salons ordered to shut and shisha banned
Germany announces new four-week 'lockdown lite' that will see all bars and restaurants closed but schools and shops stay open as Spain and Italy are hit by more anti-shutdown protests
Around 1.4% of hospitalised Covid-19 patients will suffer a stroke, scientists warn
The aims of coronavirus vaccine trials, which use tens of thousands of volunteers worldwide, is to see if the jab prevents SARS-CoV-2 infection.

But they will not reveal if the vaccines stop the chain of transmission, or prevent someone from getting severely sick or dying.

It would take several years to assess if a vaccine actually saves lives, which is why scientists have cut corners in order to develop one that at least reduces the risk of catching it.

Another obstacle in vaccinating the population is a lack of manufacturing capacity for the billions of doses required, Ms Bingham warned.

The Taskforce anticipates that most vaccines will require two doses to work, and possibly annual booster shots.

On top of that, 'the UK is committed to ensuring that everyone at risk of SARS-CoV-2 infection, anywhere in the world, has access to a safe and effective vaccine'.

Ms Bingham wrote: 'A major challenge is that the global manufacturing capacity for vaccines is vastly inadequate for the billions of doses that are needed, and the UK manufacturing capability to date has been equally scarce.

'There will not be one successful vaccine, or one single country, that is able to supply the world.

'We urgently need international cooperation to pool risks and costs, address barriers to access, and scale up the manufacturing capacity to produce sufficient doses to protect everyone at risk of SARS-CoV-2 infection globally.'

Ms Bingham revealed there are already 'deployment plans' for when a Covid-19 vaccine is ready because there will be huge logistical challenges in roll-out. These have been made for the NHS, GP surgeries, pharmacies, care home and pop-up sites.

She confirmed 'adults older than 50 years, health-care and social-care workers on the front line, and adults with underlying comorbidities' will be first in line.

A vaccine is considered key to ending the Covid-19 pandemic which has already killed 1.1million people worldwide.

ADVERTISEMENT
It's not the first time Ms Bingham has attempted to dispel hopes of a Covid-19 vaccine ending the pandemic.

She said earlier this month that not everyone - potentially only half - of the British population would be vaccinated if a jab was proven effective against the coronavirus.

If any vaccine was proven to be 95 per cent effective, which is thought to be unlikely given the short time frame scientists have been working in, it may be given to a larger number of people.

Number 10 has already ordered 340million doses of seven different experimental jabs in a spread-betting approach that banks on one of them being proven to work.

Among them are three jabs created by Oxford University, Pfizer and Janssen – owner of Johnson & Johnson – which are all in the final stages of testing. But even if there was one ready by 2021, it would only be given to the most at-risk groups first, such as the elderly and NHS workers.

Ms Bingham said only vaccines that have the potential for approval by regulators and delivery as early as the end of 2020 or, at the latest, in the second half of 2021, have been considered.

One of the most advanced vaccines, developed by AstraZeneca and the University of Oxford, is tipped as the most likely to ready first.

ADVERTISEMENT
Those created by Novavax - which Ms Bingham has received in trial - GSK and Sanofi, and Valneva 'will not be available until late in 2021', she said.

WHICH VACCINES HAVE THE UK SECURED DEALS FOR?
1. GlaxoSmithKline and Sanofi Pasteur: 60million doses

The Government revealed on July 29 it had signed a deal with pharmaceutical giants GlaxoSmithKline (GSK) and Sanofi Pasteur

If the vaccine proves successful, the UK could begin to vaccinate priority groups, such as frontline health and social care workers and those at increased risk from coronavirus, as early as the first half of next year, the Department for Business, Energy & Industrial Strategy (BEIS) said.

Human clinical studies of the vaccine will begin in September followed by a phase 3 study in December.

The vaccine is based on the existing technology used to produce Sanofi's seasonal flu vaccine. Genetic material from the surface protein of the SARS-CoV-2 virus is inserted into insect cells - the basis of Sanofi's influenza product - and then injected to provoke an immune response in a human patient.

2. AstraZeneca (manufacturing University of Oxford's): 100million

AstraZeneca, which is working in partnership with Oxford University, is already manufacturing the experimental vaccine after a deal was struck on May 17.

Professor Sarah Gilbert, who is leading the Oxford team, is confident the jab could be ready for the most vulnerable people by the end of the year.

Her comments came after the results from the first phase, published in The Lancet on July 20, showed promise.

The team have genetically engineered a virus to look like the coronavirus - to have the same spike proteins on the outside - but be unable to cause any infection inside a person. This virus, weakened by genetic engineering, is a type of virus called an adenovirus, the same as those which cause common colds, that has been taken from chimpanzees.

3. BioNTech/Pfizer: 30million

US drug giant Pfizer - most famous for making Viagra - and German firm BioNTech were revealed to have secured a deal with the UK Government on July 20.

It reported positive results from the ongoing phase 2/3 clinical trial of one called BNT162b1 on July 1. The company is still running phase 2 trials at the moment.

Pfizer's vaccine is one called an mRNA vaccine, which do not directly inject bits of the virus into the body but send genetic material.

mRNA vaccines programme the body to produce parts of the virus itself by injecting the body with a molecule that tells disease-fighting cells what to build. The immune system then learns how to fight it.

4. Valneva: 60million

The Government has given Valneva — whose vaccine is understood to be in the preclinical stages of development — an undisclosed amount of money to expand its factory in Livingston, Scotland.

While the Government revealed a 60million dose deal on July 20, the company said it had reached agreement in principle with the UK government to provide up to 100million doses.

Valneva's jab is an inactivated whole virus vaccine, meaning it injects a damaged version of the coronavirus itself into the body.

The virus has been destroyed in a way that makes it unable to cause infection, but the body still recognises it as a dangerous intruder and therefore mounts an immune response which it can remember in case of a real Covid-19 infection.

5. Janssen (Johnson & Johnson): 30million

The Government has agreed to buy 30million doses of a vaccine made by Janssen if it works.

Officials have agreed to help the company in its development of the jab by part-funding a global clinical trial. The first in-human trials of Janssen's jab began in mid-July and are being done on adults over the age of 18 in the US and Belgium.

The jab is named Ad26.COV2-S, recombinant, and is a type of jab called a viral vector recombinant vaccine.

Proteins that appear on the outside of the coronavirus are reproduced in a lab and then injected into the body to stimulate an immune reaction.

The 'Ad' part of the vaccine's name means it works using an adenovirus - a virus best known for causing the common cold - as a vehicle to transport the coronavirus genetics into the body.

6. Novavax: 60million

Britain has ordered 60million doses of a vaccine being developed by the US-based company Novavax. It will help to fund late-stage clinical trials in the UK and also boost plans to manufacture the vaccine in Britain.

Novavax's jab, named NVX-CoV2373, showed positive results in early clinical trials.

It produced an immune response in 100 per cent of people who received it, the company said, and was safe and 'generally well-tolerated'.

Novavax's candidate is also a recombinant vaccine and transports the spike proteins found on the outside of the coronavirus into the body in order to provoke the immune system.

7. Imperial College London: Unknown quantity

Imperial College London scientists are working on Britain's second home-grown hope for a jab. The candidate is slightly behind Oxford's vaccine in terms of its progress through clinical trials, but is still a major player.

The UK Government is understood to have agreed to buy the vaccine if it works but details of a deal have not yet been publicised.

Imperial's jab is currently in second-phase human trials after early tests showed it appeared to be safe.

Imperial College London will try to deliver genetic material (RNA) from the coronavirus which programs cells inside the patient's body to recreate the spike proteins. It will transport the RNA inside liquid droplets injected into the bloodstream.

Share or comment on this article: Coronavirus UK: Vaccine tsar warns first approved jabs may not work
67
shares
Comments
MOST READ NEWS
Boris Johnson warns Pfizer jab 'WON'T deliver knock-out blow' needed to end lockdown as 50 rebel...

Revealed: Soldier who glues himself to police cars and Buddhist NHS nurse mother-of-two are unmasked...

Boris Johnson's former lover Jennifer Arcuri blasts her 'puppet' ex as a 'Great Supine Protoplasmic...

None of London's boroughs are in England's top 100 Covid hotspots amid calls for the capital to be...

Britain records 532 Covid-19 deaths in highest daily total since MAY - but cases are just 2% higher...

Joe Biden calls Donald Trump's refusal to concede 'an EMBARRASSMENT' saying 'it will not help the...

Judge rules Jehovah's Witness, 15, must have blood transfusion to save her life in emotive case...

UK says YES to jab... but you go first, Boris! Poll shows three-quarters of Britons would agree to...

The Queen and rest of Royal Family WON'T be able to jump the queue for Covid vaccine, rich people...

Antivaxxers spread false claim a vaccine has been in production for years after Pfizer announcement...

Grandmother, 67, died in 'one-in-ten-million' freak accident when oxygen tank exploded 'like a Roman...

Covid-19 patients whose oxygen levels drop even slightly below 96% may face a greater risk of dying...

Briton is among four people injured in bomb blast during French remembrance service in Saudi Arabia...

Britney Spears' fans demand justice outside court after she says she'll NEVER perform again if her...

The £40BILLION bill for Boris's 'moonshot': MPs are stunned at staggering cost of PM's mass testing...

Armed police fire rubber bullets to take down 'gunman' who was 'shouting threats and aiming RIFLE at...

DON'T MISS
Victoria Beckham sports wet hair as she makes a rare make-up free appearance to give daughter Harper...
Zara McDermott appears to CONFIRM she is back together with Sam Thompson as she emerges from his hom...
Louise Thompson suffers another ill-timed social media faux pas by posting racy snaps on Remembrance...
This Morning viewers are left outraged when an official interrupts the two-minute silence for Rememb...
'I'm sad to be stepping away': Graham Norton confirms he will LEAVE his BBC Radio 2 show in December...
'My customers put a smile on my face AND boost my confidence!' How one...
Ad Feature
'You feel massively exposed': Lisa Snowdon admits she felt 'pressured' to strip off for I'm A Celeb ...
Is this where the I'm A Celeb 2020 contestants are isolating? Lavish country estate in North Wales h...
Chloe Ferry looks incredible as she showcases her washboard abs in sheer lingerie for a racy mirror...
These are the most searched for 'how tos' online - but how many can YO...
Ad Feature
'Maybe I should've done my research!' Cardi B apologises after being accused of cultural appropriati...
Khloe Kardashian looks unrecognizable in new holiday ready snap... after revealing family is STILL p...
Britain remembers its fallen heroes: Charles and Camilla arrive at Westminster Abbey to mark 100th a...
Pregnant Charlotte Dawson wipes away tears as she struggles to use blood sugar testing needles after...
Cristiano Ronaldo's girlfriend Georgina Rodriguez displays her peachy bottom as she does the splits ...
Trying for a baby? We debunk the myths and reveal the 7 tips you REALL...
Ad Feature
Lauren Goodger, 34, shows off her famous curves in workout gear after giving fans an insight into he...
'It's one of the best things I've ever done': Molly-Mae Hague shares her joy over her natural lips a...
'I felt like Harvey Weinstein was sitting on my chest': Hugh Grant makes bizarre reference as he rev...
AJ Pritchard confirmed for I'm A Celeb as he tests NEGATIVE for Covid after contracting the virus pu...
Spread some festive cheer this year with these 10 top ideas for Christ...
Ad Feature
Michelle Keegan wears pink tracksuit as she continues to film TV show Brassic on the streets of...
Strictly's Max George returns to training with professional dance partner Dianne Buswell after havin...
Veterans Day tributes from Hollywood: Mark Wahlberg, Kelly Ripa and Jamie Lee Curtis thank members o...
Gemma Collins looks every inch the diva in sequin jumpsuit as she sashays out of upmarket London hot...
Amanda Holden screams in terror after placing her hand in a box of cockroaches while taking part in ...
Larsa Pippen, 46, shows off her VERY pert derriere in bikini... after drama with ex-BFF Kim Kardashi...
Ella Eyre keeps things casual in a blue shirt and checked trousers as she takes her dog for a walk b...
Heidi Klum flashes her cleavage and supermodel legs in plunging vintage Thierry Mugler dress as she ...
Johnny Depp fans launch petition demanding he be reinstated to Fantastic Beasts 3 after 'stepping do...
MORE TOP STORIES
© Associated Newspapers Ltd
Contact usMobile apps
View desktop siteAdvertise with us
SyndicationTerms
Privacy & cookiesHow to complain
Do not sell my info

Quantum Materials Corp. (QTMM) Stock Research Links

QTMM Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hartford Students Get Boost from Hygiene Initiatives

Updated Category News Views 2

Beyond Backpacks: Essential Hygiene for Hartford Kids When September rolls around, it’s not just about those shiny new backpacks and unopened notebooks. In good ol’ Hartford, some students find themselves in need of basics that get overlooked—a stick of deodorant, a bar of soap, maybe some period products. Skimp on these, and all of a sudden, showing up for school...

Continue Reading
Freeport-McMoRan Hit with Legal Probe: What's Next?

Updated Category News Views 4

Investigating the Movers and Shakers at Freeport When legal hawks like Kahn Swick & Foti, LLC sink their teeth into something, you can bet it's not just to nibble. These folks have jumped headfirst into probing Freeport-McMoRan Inc. (NYSE:FCX), ready to dismantle any smoke screens that might have been thrown up after the unfortunate Grasberg Block Cave mine incident. The...

Continue Reading
GoDaddy Faces Class Action: Investor Stakes High

Updated Category News Views 3

GoDaddy's Legal Turbulence: What's at Stake? Sometimes riding the stock wave can hit unexpected snags, and that's what's up with GoDaddy right now. They're stuck in the middle of a securities deception storm that's sending shivers down the spine of many an investor. The Class Action Lawsuit's Core Here's what you need to know: GoDaddy, with its ticker NYSE:GDDY, is...

Continue Reading
BellRing Brands Faces Legal Probe; Fiduciary Duties Questioned

Updated Category News Views 1

What's Stirring at BellRing Brands? Hey, no time like the present to dive headfirst into this mess BellRing's found itself in. On the heels of a lackluster sales forecast, just announced about a year ago, Kahn Swick & Foti's got their magnifying glasses out, searching for any shady dealings by those running the show at BellRing Brands, LLC. Why Is BellRing in the Hot...

Continue Reading
New Concierge Pediatric Care at Weill Cornell Launches

Updated Category News Views 2

A New Way Forward in Pediatric Care When a couple of seasoned pediatricians decide it's time for something fresh, eyes and ears perk up. Enter Dr. Paul W. Chung and Dr. Jane E. Rosini, diving headfirst into a revolutionary pediatric concierge program courtesy of Concierge Choice Physicians (CCP). We're talking a substantial shake-up at Weill Cornell Medicine, aiming to...

Continue Reading
AARP New York Promotes Affordable 'Staycation' Experiences

Updated Category News Views 3

Exploring New York Without Breaking the Bank Tough times call for creative solutions, and AARP New York is on the ball. With travel costs soaring and many older New Yorkers scrimping to make ends meet, the 'Staycation' campaign steps in with an offer too good to pass up: uncovering the gems of New York right under our noses without shelling out hefty sums. The plan? Turn...

Continue Reading
Acepodia's ACE723 Clears FDA Hurdle for Hepatocellular Push

Updated Category News Views 6

Unexpected Developments from Acepodia Folks keeping a keen eye on the biotech scene might just raise an eyebrow at Acepodia's latest move. The FDA has given their nod to ACE723, an ambitious dual-payload antibody-drug conjugate (ADC) designed to wrangle with those stubborn cases of unresectable or metastatic hepatocellular carcinoma (HCC). This isn't just another day in...

Continue Reading
Kansas City's Haunts Condense Season to 13 Nights

Updated Category News Views 0

A Scary Short Season Takes Center Stage Hold onto your ghost hats, folks! The Kansas City haunt legends are shaking things up with a shorter scare season. This October, the infamous Edge of Hell and The Beast attractions are packing in the frights over just 13 nights, shifting their schedule due to rising September temperatures. Now, ain't that something? For their 52nd...

Continue Reading
Carles Puyol Joins Midea at IFA 2026, Celebrating Unity

Updated Category News Views 0

Leadership, Innovation, and Soccer Collide in Berlin When you’ve got a Barcelona legend like Carles Puyol gracing an event, it's more than just fanfare. This time around, Puyol made waves at Midea's stand during IFA 2026 in Berlin, signaling a strategic power move for both Midea and FC Barcelona. We're talking about a scene where tech innovation meets world-class...

Continue Reading
Delisting Gray Wolf Sparks Heated Hunter Nation Debate

Updated Category News Views 2

Unraveling the Gray Wolf Controversy What are we looking at here—political maneuvering wrapped in a fur coat? Trump's executive order is making some calls I didn’t see coming. By pushing to delist the gray wolf from the Endangered Species Act (ESA), he's stirring up a mix of joy, outrage, and a boatload of debate about environmental ethics, conservation priorities,...

Continue Reading

Top 5 Most Recently Viewed Articles

CLOU Unveils Innovative Water-Cooled Energy Storage Solutions

Updated Category News Views 108

CLOU Launches Aqua-E261 & Aqua-X261 Energy Storage Systems CLOU Electronics has made a significant mark in the energy sector by introducing its next-generation commercial and industrial (C&I) liquid-cooled energy storage systems, the Aqua-E261 and Aqua-X261, at a prominent solar energy expo. This reveals the company’s dedication to providing cutting-edge energy...

Continue Reading
Upcoming Earnings for Lands' End: What to Expect

Updated Category News Views 199

Upcoming Earnings for Lands' End: Insights and Expectations Lands' End (NASDAQ: LE) is on the cusp of releasing its latest quarterly earnings report. With anticipation brewing among investors, crucial insights into the company's financial health and future guidance are coming to light. Earnings Estimates and Market Reactions Analysts project that Lands' End may announce...

Continue Reading
Phagenesis Welcomes Chad Hoskins as New CEO to Drive Growth

Updated Category News Views 229

Phagenesis Welcomes Chad Hoskins as CEO Phagenesis, a pioneering company in the field of neurostimulation therapies, has announced a major leadership transition with the appointment of Chad Hoskins as Chief Executive Officer. This change comes on the heels of the company’s recent successes, including securing $42 million in Series D funding aimed at expanding the reach...

Continue Reading
Class Action Filed Against ASP Isotopes Inc. Over Misleading Claims

Updated Category News Views 229

Class Action Lawsuit Against ASP Isotopes Inc. Recently, Robbins LLP has informed investors about a class action that was filed against ASP Isotopes Inc. (NASDAQ: ASPI). This lawsuit involves individuals and entities who purchased or acquired securities related to ASP Isotopes during a specified period. The company is currently recognized as a development-stage firm that...

Continue Reading
TOMI Environmental Solutions Unveils Strategic Partnership Boost

Updated Category News Views 229

Exciting Partnership in Disinfection Solutions TOMI Environmental Solutions, Inc.® (NASDAQ: TOMZ), a leader in disinfection technologies, recently announced a significant OEM partnership with Pharma Biotech System Components LLC. This collaboration is set to elevate the effectiveness of TOMI's SteraMist Integrated System (SIS) through the integration of innovative...

Continue Reading